Complementary DNAs encoding ORFs 2 to 7 of equine arteritis virus (EAV) have been cloned into the expression vector pGEX to produce glutathione-S-transferase fusion proteins. Recombinant proteins were affinity purified and screened in ELISA with equine sera to identify immunoreactive polypeptides. The large envelope glycoprotein (GL) was identified as the most reactive to EAV-positive equine sera and an immunodominant epitope was mapped between amino acids 55 and 98 by subcloning and expression. A fusion protein covering this region and a GL-Specific synthetic peptide (residues 75 through 97) induced EAV-nentralizing antibody in vaccinated horses. The defined antigenic region of G L is likely to be exposed on the surface of the native EAV virion and consequently may be useful in the development of diagnostic tests and vaccines.
Introduction
Horses and donkeys are the only reported hosts of equine arteritis virus (EAV; Doll et al., 1957; Paweska & Barnard, 1993) . In the horse, clinical signs of infection vary widely with the most severe form resulting in fetal abortion from pregnant mares (Doll et al., 1957) and foal death (Golnik et al., 1981; Vaala et al., 1992) . Between 30-60 % of seropositive stallions persistently shed virus in their semen (Timoney et al., 1986; and infect mares through breeding. The disease then spreads by the respiratory route (McCollum et al., 1961) .
EAV is a member of the genus Arteriviridae (Cavanagh et al., 1994) , a group of small, enveloped, positivestranded RNA viruses with a genome organization, mode of replication and gene expression strategy similar to that of corona-and toroviruses (de Vries et al., 1990 (de Vries et al., , 1992 den Boon et al., 1991; Snijder et al., 1994) . The EAV virion has a diameter of 50-70 nm (Hyllseth, 1973) and consists of an isometric nucleocapsid (35 nm) surrounded by an envelope which carries ring-like surface structures with a diameter of 12-15 nm (Murphy, 1980; Horzinek, 1981) . The nucleocapsid is composed of an infectious, polyadenylated, single-stranded genomic RNA with a size of 12.7 kb (den Boon et al., 1991) and phosphorylated core protein (N) with a molecular mass * Author for correspondence. Fax +44 1638 750794.
of 12-14 kDa (Hyllseth, 1973 ; Zeegers et al., 1976) . The envelope contains a 16 kDa non-glycosylated protein (M) and N-glycosylated proteins of 25 kDa (Gs) and 30-42 kDa (G 0 (de Vries et al., 1992) .
The major structural proteins GL, M and N are encoded by ORFs 5, 6 and 7, respectively; the minor envelope glycoprotein G s is specified by ORF 2. ORFs 3 and 4 are both predicted to encode N-glycosylated membrane proteins but the products of these ORFs have not been characterized in detail. EAV G L is a heterogeneously glycosylated envelope protein responsible for the characteristic 30-42 kDa smear seen upon analysis of virus proteins in polyacrylamide gels (van Berlo et al., 1986; de Vries et al., 1992) Minor antigenic differences between EAV isolates have been demonstrated in serological studies (Fukunaga & McCollum, 1977; Fukunaga et al., 1994) . Additionally, limited genomic variation was observed by RNase T1 fingerprinting (Murphy et al., 1988 (Murphy et al., , 1992 , although sequencing studies have revealed that the EAV M and N proteins are highly conserved between isolates (Chirnside et al., 1994) .
A long-lived virus-neutralizing (VN) antibody response is induced following viral infection (Gerber et al., 1978) and is believed to be fully protective . The observation that colostrum from immune mares, but not from non-immune dams, moderates or prevents equine viral arteritis in young foals (McCollum, 1976 ) also emphasizes the role of VN antibodies in protection against EAV. A live attenuated vaccine (Doll et al., 1968; Harry & McCollum, 1981; Timoney et al., 1988) and inactivated whole virus vaccines (McCollum, 1986; Fukunaga et al., 1990 Fukunaga et al., , 1992 induce VN antibody responses in horses. Western blotting and competition ELISA data (Balasuriya et al., 1993) indicate that strongly neutralizing monoclonal antibodies recognize a single epitope on a 29 kDa EAV protein which is likely to correspond to G L. Recently Deregt et al. (1994) demonstrated that from a panel of monoclonal antibodies to the EAV N and GT, proteins all of the neutralizing antibodies recognized G~. Competitive binding assays revealed that they all bound to the same or to closely adjacent sites on the GL protein. However, the specific EAV epitope(s) inducing the protective VN response in horses remain to be identified.
In this paper we report the cloning, bacterial expression and serological reactivity of EAV glutathione-S-transferase (GST) fusion proteins to pre-and postinfection equine sera, and the equine antibody response induced by immunization with a GL-derived fusion protein and synthetic peptide.
Methods
Materials. Restriction enzymes, dNTP solutions, glutathioneSepharose 4B and the pGEX-2T and pGEX-3X expression vectors (Smith & Johnson, 1988) were obtained from Pharmacia. Calf intestinal alkaline phosphatase, lysozyme, the Klenow fragment of DNA polymerase I, DNase I, T4 DNA polymerase and T4 DNA ligase were supplied by Boehringer Mannheim. Sequenase (version 2.0) was obtained from United States Biochemical and biotin-labelled affinitypurified goat antiserum to horse IgG and streptavidin peroxidase conjugate were from Kirkegaard and Perry Laboratories.
Plasmid constructs. Plasmid DNA manipulations were performed as described previously (Sambrook et al., 1989) . EAV cDNA sequences encoding ORFs 2 to 7 were excised from cDNA clones 106 and 535 or previously generated recombinant phagemids (de Vries et al., 1990 (de Vries et al., , 1992 and inserted in-frame into pGEX-2T or pGEX-3X as indicated in Table 1 . To construct pAVI04, clone 106 was digested with DdeI and the 5' protruding ends repaired with the Klenow fragment of DNA polymerase I. The desired 0.6 kb fragment was then gel-purified and inserted into SmaI-digested pBluescript KS(+). Ligation mixtures were used to transform Escherichia coli strain TG1 (Gibson, 1984) and transformants were selected on Luria broth (LB) agar containing 100 gg/ml ampicillin.
Expression of fusion proteins. Colonies were picked into LB medium containing 100 lag/ml ampicillin and grown at 37 °C overnight. A 20-fold dilution of this culture was then grown for 2 h at 28 °C and protein expression induced by addition of 0.2 mM-IPTG. After 5 h growth at 28 °C, 1 ml of culture was centrifuged and the bacterial pellet was dissolved in 100 gl sample buffer. The sample was then incubated for 5min at 96°C and 10gl were analysed in an SDS-12.5% polyacrylamide gel (Laemmli, 1970) . DNA from clones expressing an altered GST fusion protein was subjected to restriction endonuclease analysis and sequenced by the dideoxynucleotide chain termination method with Sequenase to check the insert size and the GST-EAV cDNA junction and inserted nucleotide sequence. Sequencing was performed using the primer 5" GGCGACCATCCTCCAAA 3', located Purification of fusion proteins. Fusion proteins were affinity purified using glutathion~Sepharose 4B. A 250 ml culture of bacterial cells expressing recombinant antigen was harvested by centrifugation for 15 min at 6000 g and 4 °C, resuspended in 50 ml 10 mN-Tris-HC1 pH 8.0, 1 mM-EDTA and 100 mM-NaC1 (STE), and recentrifuged to pellet the cells. The supernatant was discarded and the cells were resuspended in 3 ml STE, 50 gl lysozyme (50 mg/ml) was added and the tube incubated at 37 °C for 15 min. The mixture was then frozen at 70 °C overnight followed by a short immersion in a boiling water bath to thaw the frozen suspension. After the addition of 30 gl 1 M-MgC12 and 20 lag DNase I the sample was incubated at 37 °C for 15 min. Triton X-100 was added to a final concentration of 1%, the mixture kept on ice for 10 rain and centrifuged for 15 min at 10000 g and 4 °C. glutathione-Sepharose 4B was added to the supernatant and the solution mixed by gentle agitation on a rotary mixer for 20 min. The gel was washed three times with PBS and the recombinant antigen eluted from the gel with reduced glutathione (5 mM-glutathione, 50 mMTris-HC1 pH 8"0). The eluate was collected in 1 ml fractions and analysed by PAGE prior to pooling fractions containing purified protein.
Peptide synthesis and coupling to keyhole limpet haemocyanin (KLH).
The oligopeptide SP25 (Table 1) was synthesized on a Milligen/ Biosearch 9400 Excell peptide synthesizer by the solid phase Fmoc procedure (Stewart & Young, 1984) . To increase its immunogenicity, SP25 was conjugated to KLH using limiting amounts of glutaraldehyde (Gullick et al., 1985) .
ELISA. Optimum concentrations of reactants were predetermined by chequerboard titration. Immulon 3 microtitre plates (Dynatech) were coated with 0-5 I~g per well of the GST, GST-EAV fusion protein or synthetic peptide diluted in 100 mu-sodium carbonate buffer pH 9"6 overnight at 4 °C. Plates were then washed three times with PBS containing 0"05 % Tween 20 (PBST) and blocked by the addition of 100 lal PBST containing 5% goat serum (PBSTG) for 1 h at 37 °C. Following washing, 100 lal of horse sera diluted 100-fold in PBSTG were added to each well and the plates incubated at 37 °C for 90 rain. Plates were washed again and 100 lal of biotin-labelled goat anti-horse IgG (1000-fold dilution in PBSTG) were added for 90 min at 37 °C. After washing, 100 gl of streptavidin peroxidase (1000-fold dilution in PBSTG) were added to each well for 30 min at room temperature. After their final wash, 100 gl of substrate solution (0"5 mg/ml ophenylenediamine dihydrochloride dissolved in 50 raM-sodium phosphate, sodium citrate buffer pH 5.0, 0.03 % sodium perborate) were added for 10 min at room temperature, and the reaction stopped by adding 50 gl 4 M-H2SO 4 to each well. The absorbance was read at 490 nm on a Molecular Devices Thermomax plate reader.
Equine sera at a 100-fold dilution had a variable background absorbance caused by non-specific binding of the equine sera to GST. Consequently the reactivity of each serum sample to GST was subtracted from that to the GST-EAV fusion protein to derive the EAV-specific A490 value. There was no discernible reactivity of horse serum with uncoated Immulon 3 plates blocked with PBSTG. Reactivities of equine sera to synthetic peptide SP25 are therefore reported as direct readings. Each serum was assayed in duplicate wells against each antigen and the mean A4a 0 value calculated.
Animal immunizations. New Zealand white rabbits were immunized subcutaneously with 100 ktg of affinity-purified GST or GST-EAV fusion protein in Freund's complete adjuvant, followed 5 weeks later by a second immunization in Freund's incomplete adjuvant. Serum was collected at regular intervals to assess the response to vaccination. KLH-SP25 was also administered subcutaneously; the rabbit was primed with 200 ~tg of conjugate emulsified in Freund's complete adjuvant and boosted at monthly intervals using 500 ~tg KLH-SP25 and Freund's incomplete adjuvant. The rabbit was bled 2 weeks after the fourth boost. For equine immunizations, affinity purified GST, FP5Rsal or peptide SP25 were mixed with polymer adjuvant (Carbomer-PD; Solvay Duphar) to a final adjuvant concentration of 0-5 %. Three groups of three Welsh ponies were immunized (deep intramuscular) with 400 lag GST (group A), 400 lag FP5Rsal (group B) or 125 lag KLH-SP25 (Group C) in a total volume of 2 ml on day 0. All animals received further immunizations on days 51 and 114, and were bled at intervals throughout the experiment.
Virus neutralization test. The neutralization test was performed as described by Senne et al. (1985) and serum titres calculated according to Karber (1931) . In each test three equine sera with stable neutralization titres were included as controls, and a virus titration ensured the correct virus dose was administered to each well.
Antisera. The field antisera used for ELISA in this study were submitted to the Animal Health Trust diagnostic laboratory.
Results

Design of fusion proteins
In this study a panel of recombinant fusion proteins (designated FP) derived from EAV ORFs 2-7 (Table 1 ; Fig. 1 a) has been used to map an immunoreactive viral epitope. In FP22 the amino-terminal signal sequence of the ORF 2 protein was absent, whereas in FP20 an additional 42 residues of the Gs ectodomain (A. de Vries et al., unpublished results) were missing. FP30 contained the entire ORF 3 coding sequence except for 7 amino acids of the putative amino-terminal signal sequence and 23 hydrophobic residues at the carboxy terminus. FP40 comprised all except 2 amino-terminal residues encoded by ORF 4 and FP50 contained amino acids 28 through 137 of the ORF 5 coding sequence, corresponding to the hydrophilic part of the G L ectodomain (de Vries et al., 1992) . We failed to produce fusion proteins containing the large internal hydrophobic domain of the G L protein (residues 116 through 191); however, on the basis of its physicochemical properties we expect this domain to be embedded in the viral envelope or to be internalized within the protein, and therefore unlikely to be of importance in the induction of host antibodies. FP60 contained all except 5 amino-terminal residues of the M protein and FP70 contained the complete N protein.
Reactivity of equine sera with fusion proteins
GST fusion proteins were expressed at 28 °C in order to optimize soluble fusion protein production (Pognonec et al., 1991) . The 26.9 kDa GST protein was expressed in bacteria transformed with pGEX-3X (Fig. 2, lane +) but not in untransformed TG1 cells (Fig. 2, lane-) . In the lanes containing material from bacteria transformed with pGEX constructs the 26"9 kDa band was replaced by a higher molecular mass band (lanes FP22 to FP70). The position of these bands corresponded approximately to the expected sizes of the recombinant fusion proteins (Table 1) . A panel of equine sera consisting of one nonneutralizing and 10 post-infection sera with EAVneutralizing antibody titres ranging from log10 0-6 to 2.5 was selected at random and assayed for reactivity in Western blots to peptides FP20 to FP70. These blots produced conflicting results as individual VN sera bound the GST-EAV fusion proteins extremely poorly, and in many cases failed to recognize any of them. As a consequence the reactivity patterns of the sera to proteins FP20 to FP70 were re-investigated by ELISA using "~ ELISA plates were coated with 0-5 gg per well of purified fusion protein or GST. Sera were tested in duplicate wells to each antigen and the absorbance read at 490 nm. The GST absorbance was subtracted from the fusion protein absorbance to derive the EAV-specific value.
affinity-purified fusion proteins as antigen ( Table 2 ). The highest ELISA A490 readings were obtained against FP50, with a clear-cut absorbance difference between post-infection VN and non-neutralizing equine sera (Table 2) . FP20, FP30, FP40 and FP60 were not specifically recognized by the post-infection sera. FP22, which contains almost the entire ectodomain of Gs, was bound at a significant level by three of the VN sera (VN titre 0.8, 1.6 and 2.3) and FP70 was recognized to a limited extent by four individual VN sera (VN titres 0"9, 1.4, 1.9 and 2.4).
Reactivity of field sera to FP50 in ELISA
In order to examine the reactivity of a wider range of equine sera to FP50 a panel of 192 field sera, comprising 96 VN (VN +) and 96 non-neutralizing (VN-) equine sera, was evaluated by ELISA. All VN + sera produced a specific A490 ~> 0.4 at a 100-fold dilution in direct ELISA to FP50 (Fig. 3 a) . A linear correlation existed between VN antibody titre and ELISA A490 value (r = 0.848), although considerable variation existed between different individuals with similar serum neutralizing antibody titres. Using the intercept value (0.326) as the cut-off point for an ELISA positive value, 33/96 VN sera were positive and no VN + sera were negative.
Determination of a major epitope on EA V G L
Although the membrane topology of the G L protein has not been formally established, its hydropathy profile (de Vries et al., 1992) imply that residues 19 to 115 are contained within the ectodomain and may be recognized by neutralizing equine sera. To test this hypothesis small parts of the ORF 5 gene were subcloned into pGEX and the individual reactivities of the purified fusion proteins were assayed in ELISA. Initially three pGEX constructs, FP51, FP52 and FP54, were made ( Fig. lb; Table 1 ), excluding the large internal hydrophobic domain which is likely to be involved in anchoring the GL protein in the membrane. These fusion proteins were screened by ELISA, with only FP52 being specifically recognized by VN equine antisera. Although abundantly expressed in bacteria, FP52 bound to glutathione-Sepharose 4B very poorly and was extremely difficult to purify to homogeneity. Consequently, a further expression construct located within GL, FP5Rsal, was made. This protein proved extremely reactive with the VN ÷ field sera in ELISA (Fig. 3 b) . The correlation coefficient determined by regression analysis for this ELISA was 0"833 with an intercept value of 0"322. Using this as the cut-off point for ELISA positive sera, 25/96 VN-sera were positive and no VN + sera were negative.
Using the algorithm of Jameson & Wolf (1988) the most immunogenic region of EAV G L was predicted to be between amino acid residues 75 through 97. A synthetic peptide, SP25, covering these residues was consequently used to study the reactivity of this part of the G L ectodomain. SP25 is located within FP5Rsal and was recognized less specifically by the panel of VN + equine antisera in ELISA (r = 0.634) than either FP50 or FP5Rsal (Fig. 3c) ; 10/96 VN-sera were positive in ELISA and 22/96 VN + sera were negative using the intercept (0-372) as the cut-off point for positive results.
Immunogenicity of G L
The immunogenicity of the first series of fusion proteins and peptide SP25 was initially tested in rabbits. FPs 20, 30, 40, 50, 60, 70 and GST failed to elicit a VN response even after multiple immunizations. However, sera from rabbits immunized with affinity-purified FP5Rsal or KLH-SP25 blocked EAV infection in virus neutralization tests. The immunogenicity of GST, FP5Rsal and SP25 was subsequently studied in a small group of Welsh ponies. Immunizations were performed on three groups of horses each comprised of three animals. Horses were vaccinated on days 0, 51 and 114, bled at regular intervals and the sera tested for EAV-specific antibodies by microneutralization assay, and ELISA to SP25 and FP5Rsal (Fig. 4a-i) .
Immunization with GST (horses 165, 270 and 310) failed to elicit any specific antibody response to EAV detectable by VN tests or ELISA (Fig. 4 a-c) . In contrast, all three animals immunized with SP25 (236, 259 and 276) produced both VN and ELISA antibodies (Fig.  4g-i) . VN antibody levels peaked directly after the second and third immunizations, and decayed within 60 days; an increased peak antibody titre followed each immunization. Horses immunized with SP25 exhibited high ELISA antibody levels specific to both SP25 and FP5Rsa 1 which peaked directly after each immunization and persisted, even in the absence of VN antibody.
The antibody response in horses immunized with FP5Rsal was more varied than that for SP25 (Fig.  4d-J) ; horse 232 did not produce neutralizing antibody to EAV in response to vaccination. However, both horses 168 and 235 had neutralizing antibody induced following the second and third immunizations with FP5Rsal. The peak VN antibody titre was lower after the third immunization compared to the response induced by the second immunization. All three animals had consistently high ELISA antibody levels to SP25, which peaked following each vaccination, but the high reactivity of these sera to GST after the second immunization masked any direct antibody response to the EAV-specific domain of FP5Rsal. As with the three horses immunized with SP25, ELISA antibody levels to SP25 in the FP5Rsal-vaccinated group persisted in the absence of specific EAV-neutralizing antibody.
Discussion
The pGEX bacterial expression system allows the production of abundant, easily purified fusion proteins (Smith & Johnson, 1988) which are useful for defining virus epitopes (Lopez de Turiso et al., 1991) and as ELISA and vaccine antigens (Johnson et al., 1989; Thomas et al., 1992) . In this study we have utilized GST fusion proteins to identify the EAV G L protein as an important viral antigen; post-infection, VN equine sera predominantly recognized bacterial fusion proteins containing GL. The approach was further used to map the immunodominant domain to a particular region within the G L ectodomain. Finally, this domain, as well as a synthetic oligopeptide contained within it, successfully induced a VN antibody response in horses.
Fusion proteins comprised of Gs, M, and N, and of polypeptides encoded by EAV ORFs 3 and 4, were poorly immunoreactive with post-infection equine sera in ELISA. In contrast, G L fusion proteins, uniquely amongst the EAV structural protein repertoire, reacted strongly. Coarse mapping of the immunoreactive epitope(s) was accomplished by subcloning of ORF 5 to produce a series of smaller recombinant polypeptides. Fusion proteins including G L residues 55 through 98 were reactive in the ELISA; in the absence of these residues post-infection, VN equine sera did not bind to the fusion protein. A synthetic peptide containing residues 75 through 97 was also reactive in ELISA with these sera, although with decreased specificity and sensitivity compared to the immunoreactive fusion proteins FP50 and FP5Rsal. The observations suggest that an important linear epitope exists between residues 55 and 98 of the G L protein, although other linear and/or conformational epitopes in the protein cannot be excluded. The single N-glycosylation site present within GL lies within the immunoreactive region at residue 56.
The poor reactivity of the fusion proteins derived from the other EAV ORFs both in Western blots and in direct ELISA does not preclude that the corresponding viral proteins have a role in promoting the equine immune response to EAV. In fact, in addition to G L, the viral N and M proteins are recognized in Western blots to whole virus antigen and can also be immunoprecipitated from lysates of EAV-infected cells by post-infection horse sera (data not shown). Prokaryotic expression products may fail to react for many reasons. Fusion proteins may not effectively mimic the native viral proteins due to differences in polypeptide folding, disulphide bond formation or in post-translational modification, notably N-glycosylation. Also, expression of incomplete proteins may have conformational effects. With one exception (FP70) all the fusion proteins in our study omitted portions of terminal or internal domains of the EAV proteins. Finally, altered ELISA conditions, optimized for the individual fusion proteins, may have made some differences to equine serum reactivity to individual polypeptides.
Finding G L the immunodominant EAV protein was not unexpected in view of its structure, position and abundance in the virion. GL is the major viral envelope glycoprotein which, together with M and N comprises more than 95 % of the total virion protein (de Vries et al., 1992) . N is contained within the virion interior while the M protein is largely embedded in the envelope membrane. In contrast, the large hydrophilic amino-terminal half of the G~ protein is exposed and apparently protrudes from the virion surface.
The strong reactivity of the GL-based fusion proteins with VN ÷ field sera from horses in ELISA may form the basis for a reliable, rapid and cheap serological test (Chirnside et al., 1995) to replace virus neutralization (Senne et al., 1985) and complement fixation tests (Fukunaga & McCollum, 1977) . Such an assay to detect previously EAV-infected animals will allow more widespread screening of horses than at present, and reduce the possibility of persistently infected animals being used for breeding. Previous EAV ELISA tests, based on the use of purified whole virus as antigen, have suffered from poor specificity (Cook et al., 1989) . The significance of antigenic variation for the reliability of a G~-based ELISA will have to be established. Complement fixation (Fukunaga & McCollum, 1977) and cross-neutralization studies using monovalent equine antisera in homologous and heterologous virus neutralization tests (Fukunaga et al., 1994) have indicated that minor antigenic variation between EAV isolates does exist. At the genetic level, RNase T1 oligonucleotide fingerprinting of viral genomes (Murphy et al., 1988) and sequence analysis of EAV M and N genes from different isolates (Chirnside et al., 1994) have also demonstrated the existence of variation.
Both a GL subunit (residues 55 through 98) and a GLspecific oligopeptide (residues 75 through 97) induced VN antibodies in horses following immunization. This is consistent with the recent observation that neutralizing monoclonal antibodies to EAV are invariably directed to the G L protein. Balasuriya et al. (1993) described a panel of six such monoclonal antibodies that recognized a single site on a 29 kDa glycoprotein. Deregt et al. (1994) , in addition to identifying G L as the viral protein with which neutralizing antibodies reacted, also demonstrated that one monoclonal antibody still recognized the G L protein when most of the carboxy-terminal half (residues 117 through 211) was deleted. This antibody competed in ELISA with all the other GL-Specific monoclonal antibodies. These data support our finding that the G L ectodomain is the immunogenic and biologically most relevant domain.
Although the importance of the host cellular immune response to EAV remains to be investigated, equine vaccination schedules with both live attenuated and inactivated whole virus preparations probably rely on the induction of neutralizing antibodies. Host neutralizing antibodies are known to persist for many years after infection (Gerber et al., 1978) and correlate closely with protection from re-infection (McCollum, 1986; Fukunaga et al., 1990 Fukunaga et al., , 1992 . The subunit-vaccinated horses in our study maintained high levels of GL-specific antibody over long time periods. In contrast, VN activity was only intermittently detectable for short periods after each booster immunization, and the peak levels and duration decreased with each successive immunization. Although ELISA and VN antibody peaks concurred, the rapid turnover and low levels of the neutralizing activity as well as the occurrence of one non-responder animal in virus neutralization tests suggest that the whole virus antigen responsible for inducing VN antibody in horses differs in composition or presentation from the subunits studied.
The Arteriviridae is currently comprised of EAV, lactate dehydrogenase-elevating virus (LDV), simian haemorrhagic fever virus and porcine respiratory and reproductive syndrome virus (PRRSV) (Plagemann & Moennig, 1992; Cavanagh et al., 1994) . These intracellular budding viruses are very similar both structurally and with respect to their replication (Plagemann & Moennig, 1992; Conzelmann et al., 1993) . Interestingly, comparative analysis of the predicted ORF 5 products of these viruses revealed a number of conserved features indicating that despite the absence of significant sequence similarities these proteins are the structural homologues of the EAV G L protein. Serologically no cross-reactivity exists between EAV, LDV and PRRSV (van Berlo et al., 1983; Wensvoort et al., 1992) . The host immune responses to these viruses, in particular the temporal induction and biological activity of neutralizing antibody, are also quite different. LDV-and PRRSVneutralizing antibodies appear 15 months after infection and are relatively inefficient in neutralization (Harty & Plagemann, 1988; Frey et al., 1992) . In contrast, effective neutralizing antibodies are circulating in the horse within 14 days of infection with EAV (Gerber et al., 1978) and efficiently clear circulating virus. However, a carrier state exists for EAV (Timoney et al., 1986) , with virus present in the accessory sex cells and semen of persistently shedding stallions (Neu et al., 1988) . The primary target cells of other arteriviruses are host macrophages where these viruses can establish asymptomatic, persistent infections unaffected by the host immune response (Plagemann & Moenning, 1992) . However, the specific mechanism that allows EAV to escape immune surveillance in the presence of high titres of neutralizing antibody requires further study. 
